SUCCESS STORIES

NuLabel Technologies

Companies consume over 2 trillion labels a year to label everything from boxes to wine bottles. Almost every time a label is printed, half of it goes to waste. The waste is the label’s liner, the non-recyclable, non-stick backing. End-users not only throw away half of what they print, they also throw away half of what they pay for. The liner is the most expensive part of the label.

NuLabel Technologies, Inc. is an adhesive and printer hardware technology company developing innovative label platforms to help companies cut cost and reduce waste. Founded in 2009 by Ben Lux, Max Winograd and Mike Woods, NuLabel has developed patent pending liner-free label technology that uses an activateable adhesive to eliminate the need for the liner.

Born out of a Brown University engineering project, NuLabel recently moved into its new headquarters at 349 Eddy Street in the heart of Providence's knowledge district.

In addition to its activateable adhesive, NuLabel has developed activation hardware to seamlessly integrate their liner-free platform into a company’s existing labeling operation. This low cost, zero waste solution offers numerous benefits.

NuLabel’s liner-free labels cost significantly less than linered labels, double printing capacity, boost employee productivity, reduce storage and freight costs, and eliminate waste. To learn more about the impact of liner-free labels on your label operation, you can contact them at 401-305-5075, and they will send you a copy of "The Impact of Labels," a case study about what going liner-free can do for your business.

Inside NuLabel







MicroTissues

MicroTissues Inc. is a privately held Rhode Island company advancing technologies and applications of 3D cell culture.  The company's products create more natural and reliable environments based on cell-to-cell interactions in convenient and consistent formats that generate high content information.  MicroTissues’ lead line of products, the 3D Petri DishTM, is serving the needs of researchers in a wide range of areas including cancer research, stem cell biology, toxicity testing, developmental biology, drug discovery, regenerative medicine and tissue engineering.  In addition to products for basic reasearch, MicroTissues is using its platform technology to pursue applications in drug discovery and cell therapy. 
 
Last year Dr. Jeffrey Morgan, MicroTissues' founder and an Associate Professor of Medical Science and Engineering at Brown University, collaborated with Dr. Sandra Carson, Professor of Obstetrics and Gynecology at the Warren Alpert Medical School at Brown University and Director of the Division of Reproductive Endocrinology and Infertility at Women & Infants Hospital, to develop the first artificial ovary using the 3D Petri Dish.  Their work was subsequently recognized by Time magazine as one of the top 10 medical breakthroughs of 2010.  Other researchers recognized for the work were Jared Robins, Toni-Marie Ferruccio, Richard Moore and Margaret Steinhoff, all of Brown University.
 
This month MicroTissues exhibited at BioMethods Boston Conference 2011, hosted by Harvard University.  This event brings together the top academic and industrial researchers with industry executives in a common focus on the direction of technology in drug discovery, regenerative medicine and other technologies.

For more information about MicroTissues, please visit www.microtissues.com.